• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    iRhythm Technologies to Participate in Upcoming Investor Conferences

    5/21/25 4:45:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences.

    • William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time)
    • Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time)
    • Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time)

    Interested parties may access live and archived webcasts of the presentations on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com.

    About iRhythm Technologies, Inc.

    iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at irhythmtech.com.

    Investor Contact

    Stephanie Zhadkevich

    [email protected]

    Media Contact

    Kassandra Perry

    [email protected]



    Primary Logo

    Get the next $IRTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    2/7/2023$150.00Overweight
    Wells Fargo
    11/7/2022Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $IRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

      iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

      2/29/24 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Derrick Sung Joins Aerin Medical as Chief Financial Officer

      A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

      11/20/23 9:00:00 AM ET
      $IRTC
      $LUNG
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

      SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

      6/6/23 9:00:39 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iRhythm upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

      5/2/25 8:03:46 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Wells Fargo resumed coverage on iRhythm with a new price target

      Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00

      12/3/24 7:33:58 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on iRhythm with a new price target

      Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00

      10/4/24 7:40:56 AM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Patterson Chad sold $54,450 worth of shares (363 units at $150.00), decreasing direct ownership by 0.72% to 49,865 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      6/11/25 4:21:32 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Risk Officer Shrishrimal Sumi was granted 176 shares and sold $225,458 worth of shares (1,608 units at $140.21), decreasing direct ownership by 4% to 34,685 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      6/3/25 4:18:04 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • Chief Accounting Officer Rosenbaum Marc W. was granted 294 shares and sold $97,586 worth of shares (696 units at $140.21), decreasing direct ownership by 3% to 11,105 units (SEC Form 4)

      4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

      6/3/25 4:17:32 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care

    $IRTC
    Financials

    Live finance-specific insights

    See more
    • iRhythm Technologies Announces First Quarter 2025 Financial Results

      SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu

      5/1/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

      SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di

      4/17/25 4:30:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care
    • iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

      SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ

      2/20/25 4:05:00 PM ET
      $IRTC
      Medical/Dental Instruments
      Health Care